398 related articles for article (PubMed ID: 27521324)
1. Selection of Patients With Myelodysplastic Syndrome for Allogeneic Hematopoietic Stem Cell Transplantation.
Mishra A; Anasetti C
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S49-52. PubMed ID: 27521324
[TBL] [Abstract][Full Text] [Related]
2. [Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review].
Zhang Z; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):969-74. PubMed ID: 18718102
[TBL] [Abstract][Full Text] [Related]
3. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
[TBL] [Abstract][Full Text] [Related]
4. Correlation of somatic mutations with outcome after FLAMSA-busulfan sequential conditioning and allogeneic stem cell transplantation in patients with myelodysplastic syndromes.
Christopeit M; Badbaran A; Alawi M; Zabelina T; Zeck G; Wolschke C; Ayuk F; Kröger N
Eur J Haematol; 2016 Sep; 97(3):288-96. PubMed ID: 26680262
[TBL] [Abstract][Full Text] [Related]
5. Transplants in myelodysplastic syndromes.
Wetzko K; Platzbecker U
Hematol Oncol Clin North Am; 2014 Dec; 28(6):1011-22. PubMed ID: 25459176
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myelodysplastic Syndrome Harboring Trisomy 8.
Konuma T; Miyazaki Y; Uchida N; Ohashi K; Kondo T; Nakamae H; Takahashi S; Mori T; Ozawa Y; Kato C; Iwato K; Fukuda T; Ichinohe T; Atsuta Y; Ishiyama K;
Biol Blood Marrow Transplant; 2017 Jan; 23(1):75-80. PubMed ID: 27777139
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes.
Sharma P; Shinde SS; Damlaj M; Hefazi Rorghabeh M; Hashmi SK; Litzow MR; Hogan WJ; Gangat N; Elliott MA; Al-Kali A; Tefferi A; Patnaik MM
Leuk Lymphoma; 2017 Apr; 58(4):872-881. PubMed ID: 27687869
[TBL] [Abstract][Full Text] [Related]
9. Hematopoietic stem cell transplantation for myelodysplastic syndrome.
Parmar S; de Lima M
Biol Blood Marrow Transplant; 2010 Jan; 16(1 Suppl):S37-44. PubMed ID: 19857589
[TBL] [Abstract][Full Text] [Related]
10. Current State of the Art: Management of Higher Risk Myelodysplastic Syndromes.
Komrokji RS
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S39-43. PubMed ID: 27521322
[TBL] [Abstract][Full Text] [Related]
11. Timing of allogeneic stem cell transplantation for myelodysplastic syndromes and aplastic anemia.
Cutler C
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):77-81. PubMed ID: 25696838
[TBL] [Abstract][Full Text] [Related]
12. Optimal positioning of hematopoietic stem cell transplantation for older patients with myelodysplastic syndromes.
Abel GA; Koreth J
Curr Opin Hematol; 2013 Mar; 20(2):150-6. PubMed ID: 23298879
[TBL] [Abstract][Full Text] [Related]
13. The role of hematopoietic stem cell transplantation in myelodysplastic syndrome.
Thompson JE; Luger SM
Oncology (Williston Park); 2005 Apr; 19(4):533-42; discussion 542-4, 547-8. PubMed ID: 15934520
[TBL] [Abstract][Full Text] [Related]
14. Favorable Outcomes With Tumor Burden Reduction Following Administration of Hypomethylating Agents Before Allogeneic Hematopoietic Cell Transplantation in Patients With Higher Risk Myelodysplastic Syndrome.
Park S; Baek DW; Sohn SK; Ahn JS; Kim HJ; Shin HJ; Chung JS; Lee SM; Lee WS; Lim SN; Lee YJ; Choi Y; Lee HS; Cho YY; Lee GW; Moon JH
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e367-e373. PubMed ID: 31060990
[TBL] [Abstract][Full Text] [Related]
15. Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts.
Yahng SA; Kim M; Kim TM; Jeon YW; Yoon JH; Shin SH; Lee SE; Eom KS; Lee S; Min CK; Kim HJ; Kim DW; Lee JW; Min WS; Kim YJ
Oncotarget; 2017 Feb; 8(7):12342-12354. PubMed ID: 27729615
[TBL] [Abstract][Full Text] [Related]
16. [New progress of study on hematopoietic stem cell transplantation for myelodysplastic syndromes].
Wu B; Wei Y; Zhang Q
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Apr; 20(2):510-3. PubMed ID: 22541129
[TBL] [Abstract][Full Text] [Related]
17. [Treatment for myelodysplastic syndrome: with a focus on the low-risk group].
Gotoh A
Rinsho Ketsueki; 2017; 58(10):1951-1959. PubMed ID: 28978837
[TBL] [Abstract][Full Text] [Related]
18. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
Flotho C; Sommer S; Lübbert M
Semin Cancer Biol; 2018 Aug; 51():68-79. PubMed ID: 29129488
[TBL] [Abstract][Full Text] [Related]
19. Monosomy 7 associated with pediatric acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): successful management by allogeneic hematopoietic stem cell transplant (HSCT).
Trobaugh-Lotrario AD; Kletzel M; Quinones RR; McGavran L; Proytcheva MA; Hunger SP; Malcolm J; Schissel D; Hild E; Giller RH
Bone Marrow Transplant; 2005 Jan; 35(2):143-9. PubMed ID: 15558042
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndrome.
Cutler C
Hematology Am Soc Hematol Educ Program; 2010; 2010():325-9. PubMed ID: 21239814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
